625 related articles for article (PubMed ID: 29494592)
1. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
2. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
[TBL] [Abstract][Full Text] [Related]
3. More medicines for children: impact of the EU paediatric regulation.
Nordenmalm S; Tomasi P; Pallidis C
Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
5. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
6. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
8. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
9. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
10. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
Chin WW; Joos A
Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
[TBL] [Abstract][Full Text] [Related]
11. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
12. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
[TBL] [Abstract][Full Text] [Related]
13. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013.
Deane BR; Sivarajah J
Curr Med Res Opin; 2017 Mar; 33(3):473-478. PubMed ID: 27869482
[TBL] [Abstract][Full Text] [Related]
15. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
16. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
18. Three years of paediatric regulation in the European Union.
Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
[TBL] [Abstract][Full Text] [Related]
19. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
20. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Rocchi F; Tomasi P
Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
